Drugmaker Gilead said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates, mostly in Africa, Southeast Asia and the Caribbean.

It’s been called the closest the world has ever come to a vaccine against AIDS. The twice-yearly shot was 100% effective in preventing HIV infections in a study of women, and results published Wednesday show it worked nearly as well in men.